ConCallIQ
Go Pro
DRREDDY Diversified 25 Oct 2023

Dr. Reddy's Laboratories Limited — Q2 FY24

Dr.

bullish high
Compare with...
Revenue ₹6,880 Cr +9%
EBITDA ₹2,181 Cr +30%
EBITDA Margin 31.7%
Duration
Read Time 1 min read

✓ Verified against BSE filing

Delivery score0%
Due this quarter1
Delivered0
Missed1

Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.

Q1 FY24

U.S. growth momentum to continue

Expects sustained strong performance in North America generics, including base business growth and new product launches.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1